<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02847065</url>
  </required_header>
  <id_info>
    <org_study_id>RC15_0421</org_study_id>
    <nct_id>NCT02847065</nct_id>
  </id_info>
  <brief_title>The Association Between Advancing Age and Mortality at 30 Days in Patients With Bacteremia E. Coli Beta-lactamase Phenotype Extended Spectrum RC15_0421</brief_title>
  <acronym>MoBaCo</acronym>
  <official_title>Study Single-center, Uncontrolled, Retrospective, the Association Between Advancing Age and Mortality at 30 Days in Patients With Bacteremia E. Coli Beta-lactamase Phenotype Extended Spectrum</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <brief_summary>
    <textblock>
      In the US and Europe, bacteremia are ranked the 7th leading cause of death from all causes.&#xD;
      E. coli is one of the main microorganism involved, responsible for 30% to 45% of bacteremia.&#xD;
      In Europe, bacteremia E. coli, including BLSE phenotype, have a strong impact on public&#xD;
      health, causing increased mortality, particularly in the elderly, and an increase in the&#xD;
      average hospital stay. However, few studies have specifically concerned with the criteria&#xD;
      associated with mortality of elderly patients with BLSE E. coli bacteremia. Finally,&#xD;
      improving epidemiological knowledge of the elderly patients with bacteremia due to BLSE E.&#xD;
      coli has importance in terms of public health and is a prerequisite to the development of&#xD;
      preventive strategies and to improve the short-term prognosis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 3, 2015</start_date>
  <completion_date type="Actual">April 30, 2016</completion_date>
  <primary_completion_date type="Actual">April 30, 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Association between advancing age and mortality at 30 days in patients with bacteremia E. coli beta-lactamase phenotype extended spectrum.</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <enrollment type="Actual">144</enrollment>
  <condition>Beta-lactamase Extended Spectrum, E. Coli, Elderly, Mortality, Risk Factor</condition>
  <eligibility>
    <study_pop>
      <textblock>
        All data concerning blood cultures analyzed in the bacteriology department of University&#xD;
        Hospital of Nantes are stored digitally, particularly E. coli ESBL. Thus, the extraction of&#xD;
        these data will allow the retrospective inclusion of patients and enhance the feasibility&#xD;
        of the study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients with positive blood culture E. coli BLSE will be included in the study.&#xD;
             Bacteremia E. coli BLSE will be defined as the identification of one or more blood&#xD;
             cultures positive for E. coli BLSE in patients with clinical criteria of systemic&#xD;
             inflammatory response, at least two of the following 4 criteria:&#xD;
&#xD;
               -  temperature&gt; 38 ° C or &lt; 36 ° C;&#xD;
&#xD;
               -  heart rate&gt; 90 beat / min;&#xD;
&#xD;
               -  respiratory rate &gt; 20 c / min or PaCO2 &lt; 32 mmHg;&#xD;
&#xD;
               -  WBC &gt; 12,000 / microL or &lt; 4000 / microL or 10% immature forms&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  For each patient included, only the first episode of bacteremia will be included in&#xD;
             the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>105 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 21, 2016</study_first_submitted>
  <study_first_submitted_qc>July 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2016</study_first_posted>
  <last_update_submitted>September 20, 2021</last_update_submitted>
  <last_update_submitted_qc>September 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bacteremia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

